Extended Data Fig. 3: Central administration of mGIPR-Ab/P3 peptide-antibody conjugate induces sustained weight loss in obese mice. | Nature Metabolism

Extended Data Fig. 3: Central administration of mGIPR-Ab/P3 peptide-antibody conjugate induces sustained weight loss in obese mice.

From: GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice

Extended Data Fig. 3: Central administration of mGIPR-Ab/P3 peptide-antibody conjugate induces sustained weight loss in obese mice.

ICV-cannulated DIO mice were randomized into groups to receive 25 µg/µL/mouse IgG1 or 1, 5, 10, or 25 µg/µL/mouse mGIPR-Ab/P3. Mice were dosed ICV every 4 days for 5 treatments. (a) Percent change in body weight from day 0, (b) body weight, and (c) food intake was measured up to 44 days. (A-C) 25 µg/µL/mouse IgG1 (n=5), 1 µg/µL/mouse mGIPR-Ab/P3 (n=6), 5 µg/µL/mouse mGIPR-Ab/P3 (n=6), 10 µg/µL/mouse mGIPR-Ab/P3 (n=6), or 25 µg/µL/mouse mGIPR-Ab/P3 (n=6). (A-B) Two-way ANOVA with Tukey’s test for multiple comparisons, (C) mixed-effects analysis with Tukey’s test for multiple comparisons, *p < 0.05 vs. IgG1 control. Data represent mean ± SEM. ANOVA = Analysis of Variance; DIO = diet-induced obese; ICV = intracerebroventricular.

Source data

Back to article page